Evidence map›Paper›PMID 35068281›Full record

ReviewExpert opinion on therapeutic targets2022

Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath.

Kate C Chiang, John G Rizk, Deanna J Nelson, Lakshmanan Krishnamurti, Selvakumar Subbian, John D Imig, Imran Khan, Srinivasa T Reddy, Ajay Gupta

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert opinion on therapeutic targets, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 1 country.

Kate C ChiangKARE Biosciences, Orange, CA, USA.
John G RizkDepartment of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA.ORCID 0000-0002-5216-8695
Deanna J NelsonNorth Carolina State University, Raleigh, NC, USA.
Lakshmanan KrishnamurtiDepartment of Pediatric Hematology and Oncology, Yale School of Medicine, New Haven, CT, USA.
Selvakumar SubbianRutgers University, New Jersey Medical School and Public Health Research Institute, Newark, NJ, USA.
John D ImigDrug Discovery Center and Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, USA.
Imran KhanDepartment of Pathology and Laboratory Medicine, the University of California at Davis, Sacramento, CA, USA.
Srinivasa T ReddyDepartments of Medicine, and Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Ajay GuptaCharak Foundation, Orange, CA.
Medical College of Wisconsin · USNorth Carolina State University · USRutgers, The State University of New Jersey · USUniversity of California, Davis · USUniversity of California, Irvine · USUniversity of California, Los Angeles · USUniversity of Maryland, Baltimore · USYale University · US

Funding

Vascular Rho-kinase Signaling in Angiotensin II hypertenP01HL074167 · NHLBI · MEDICAL COLLEGE OF GEORGIA (MCG) · PI WEBB, R CLINTON · 2004 to 2008
$10.5M
Endothelial Epoxygenase, Kidney Injury, and Blood Pressure RegulationR01DK126452 · NIDDK · UNIV OF ARKANSAS FOR MED SCIS · PI IMIG, JOHN D · 2021 to 2025
$2.6M
NHLBI NIH HHS P01 HL074167NIDDK NIH HHS R01 DK126452
6 · The paper itself

Abstract

introductionIn COVID-19 pneumonia, there is a massive increase in fatty acid levels and lipid mediators with a predominance of cyclooxygenase metabolites, notably TxB AREAS COVERED: Evidence supporting the role of TxA EXPERT OPINION: Ramatroban, a dual blocker of TP and DP2 receptors, has demonstrated efficacy in animal models of respiratory dysfunction, atherosclerosis, thrombosis, and sepsis, as well as preliminary evidence for rapid relief from dyspnea and hypoxemia in COVID-19 pneumonia. Ramatroban merits investigation as a promising antithrombotic and immunomodulatory agent for chemoprophylaxis and treatment.

Indexed as

COVID-19COVID-19 Drug TreatmentThrombosisAnimalsCarbazolesChemopreventionHumansInflammationPost-Acute COVID-19 SyndromeSARS-CoV-2SulfonamidesCarbazolesramatrobanSulfonamidesacute kidney injuryanti-plateletantithromboticARDSCOVID-19cyclooxygenase (COX)fibrosisIL-13immunomodulatorinterferonischemialong-haul COVIDlymphopeniapharmacotherapyplateletsprostaglandin D2RamatrobanSARS-CoV-2thromboinflammationthrombosisthromboxane A2

Identifiers

PMID35068281
PMCPMC10119876
OpenAlexW4207083252

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.